Remicade and Bumetanide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Remicade (infliximab) and Bumetanide (bumetanide). Common drug interactions include intestinal obstruction among females and acute coronary syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Remicade and Bumetanide. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

What is Bumetanide?

Bumetanide has active ingredients of bumetanide. It is often used in fluid retention. eHealthMe is studying from 20,532 Bumetanide users. Check the latest studies of Bumetanide.

On Jul, 15, 2026

35 people who take Remicade and Bumetanide together, and have interactions are studied.

Remicade and Bumetanide drug interactions.

What are the common drug interactions of Remicade and Bumetanide, by gender? *:

female:

Intestinal obstruction
Intestinal perforation (complete penetration of the wall of the intestine)
Light chain analysis increased
Lipase increased
Malaise (a feeling of general discomfort or uneasiness)
Megacolon (a very dilated colon)
Multiple myeloma (cancer of the plasma cells)
Myalgia (muscle pain)
Neck pain
Obliterative bronchiolitis (bronchiolar inflammation)

male:

Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood)
Blood glucose decreased
Cardiac failure congestive
Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
Disease recurrence
Electrocardiogram t wave amplitude decreased
Lower respiratory tract infection
Malaise (a feeling of general discomfort or uneasiness)
Myocardial ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased)
Myocarditis (inflammation of heart muscle myocardium)

What are the common drug interactions of Remicade and Bumetanide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Abdominal pain
Clostridial infection (infectious conditions by clostridium bacteria)
Decreased appetite
Diarrhoea
Gastrointestinal infection (infection of stomach and intestine)
General physical health deterioration (weak health status)
Haemorrhage (bleeding)
Intestinal obstruction
Intestinal perforation (complete penetration of the wall of the intestine)
Malaise (a feeling of general discomfort or uneasiness)

40-49:

n/a

50-59:

Drug ineffective
Metastatic malignant melanoma (spreadable cancer tumour of melanine)
Atelectasis (partial or complete collapse of the lung)
Breast pain
Eyelid oedema (eyelids are swollen and contain excessive fluid)
Infusion related reaction
Neck pain
Obliterative bronchiolitis (bronchiolar inflammation)
Obstructive airways disorder (a progressive disease that makes it hard to breathe)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)

60+:

Rectal haemorrhage (bleeding from anus)
Pneumonia
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blood glucose decreased
Bradycardia (abnormally slow heart action)
Death
Disorientation (disability in which the senses of time, direction, and recognition of people and places)
Dyspnoea (difficult or laboured respiration)
Dyspnoea exertional (breathlessness or shortness of breath)
Escherichia infection (bacterial infection by escherichia coli)

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 14 people, 40.00%
Hereditary Angioedema (recurrent episodes of severe swelling): 3 people, 8.57%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 5.71%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 5.71%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and Bumetanide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously